Alebund Pharmaceuticals Completes 8.51 Million-Share Over-Allotment, Total Issued Capital Rises to 348.37 Million

Bulletin Express08-05

Alebund Pharmaceuticals (Jiangsu) Limited issued and allotted 8.51 million H shares on 29 July 2026 following the full exercise of the over-allotment option disclosed on 24 July 2026. The shares were priced at HKD 22.60 each, implying gross proceeds of approximately HKD 192.40 million.

The transaction lifted the company’s issued H shares to 235.64 million from 227.12 million at the end of June. Unlisted shares remained unchanged at 112.73 million. Consequently, total issued share capital expanded to 348.37 million shares, compared with 339.85 million in the previous month.

The company confirmed that it continues to meet the Hong Kong Exchange’s public-float requirement, with no treasury shares outstanding. During the reporting period, Alebund Pharmaceuticals reported no movements related to share options, warrants, convertibles or other equity instruments.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1154239524?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-05 16:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154239524","market":"us","top_or_hot":-1,"title":"Alebund Pharmaceuticals Completes 8.51 Million-Share Over-Allotment, Total Issued Capital Rises to 348.37 Million","media":"Bulletin Express","content":"<p>Alebund Pharmaceuticals (Jiangsu) Limited issued and allotted 8.51 million H shares on 29 July 2026 following the full exercise of the over-allotment option disclosed on 24 July 2026. The shares were priced at HKD 22.60 each, implying gross proceeds of approximately HKD 192.40 million.</p>\n<p>The transaction lifted the company’s issued H shares to 235.64 million from 227.12 million at the end of June. Unlisted shares remained unchanged at 112.73 million. Consequently, total issued share capital expanded to 348.37 million shares, compared with 339.85 million in the previous month.</p>\n<p>The company confirmed that it continues to meet the Hong Kong Exchange’s public-float requirement, with no treasury shares outstanding. During the reporting period, Alebund Pharmaceuticals reported no movements related to share options, warrants, convertibles or other equity instruments.</p>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alebund Pharmaceuticals Completes 8.51 Million-Share Over-Allotment, Total Issued Capital Rises to 348.37 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlebund Pharmaceuticals Completes 8.51 Million-Share Over-Allotment, Total Issued Capital Rises to 348.37 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-05 16:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Alebund Pharmaceuticals (Jiangsu) Limited issued and allotted 8.51 million H shares on 29 July 2026 following the full exercise of the over-allotment option disclosed on 24 July 2026. The shares were priced at HKD 22.60 each, implying gross proceeds of approximately HKD 192.40 million.</p>\n<p>The transaction lifted the company’s issued H shares to 235.64 million from 227.12 million at the end of June. Unlisted shares remained unchanged at 112.73 million. Consequently, total issued share capital expanded to 348.37 million shares, compared with 339.85 million in the previous month.</p>\n<p>The company confirmed that it continues to meet the Hong Kong Exchange’s public-float requirement, with no treasury shares outstanding. During the reporting period, Alebund Pharmaceuticals reported no movements related to share options, warrants, convertibles or other equity instruments.</p>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09637","symbol_name":"礼邦医药-B","start_time":0,"source_url":"","article_id":"1154239524","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154239524","pubTimestamp":1785919927,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Alebund Pharmaceuticals (Jiangsu) Limited issued and allotted 8.51 million H shares on 29 July 2026 following the full exercise of the over-allotment option disclosed on 24 July 2026. The shares were...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09637":"礼邦医药-B"},"translate_title":"Alebund Pharmaceuticals完成851万股超额配售，总发行股本增至3.4837亿股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09637":1},"content_text":"Alebund Pharmaceuticals (Jiangsu) Limited issued and allotted 8.51 million H shares on 29 July 2026 following the full exercise of the over-allotment option disclosed on 24 July 2026. The shares were priced at HKD 22.60 each, implying gross proceeds of approximately HKD 192.40 million.\nThe transaction lifted the company’s issued H shares to 235.64 million from 227.12 million at the end of June. Unlisted shares remained unchanged at 112.73 million. Consequently, total issued share capital expanded to 348.37 million shares, compared with 339.85 million in the previous month.\nThe company confirmed that it continues to meet the Hong Kong Exchange’s public-float requirement, with no treasury shares outstanding. During the reporting period, Alebund Pharmaceuticals reported no movements related to share options, warrants, convertibles or other equity instruments.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1154239524","isCrawlerRequest":true}